Cargando…

Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab

Detalles Bibliográficos
Autores principales:	Raimondo, Annunziata, Guglielmi, Giulia, Marino, Carlo, Ligrone, Luigi, Lembo, Serena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063687/ https://www.ncbi.nlm.nih.gov/pubmed/33912637 http://dx.doi.org/10.1016/j.jdcr.2021.03.008

Ejemplares similares

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Erythrodermic psoriasis after discontinuation of ixekizumab
por: Potter, Kathryn Anne, et al.
Publicado: (2017)

Ixekizumab May Improve Renal Function in Psoriasis
por: Amoruso, Giuseppe Fabrizio, et al.
Publicado: (2021)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2022)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient
por: Megna, Matteo, et al.
Publicado: (2022)

A case of pediatric psoriasis successfully and rapidly treated with ixekizumab
por: Megna, Matteo, et al.
Publicado: (2021)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
por: Lobo, Yolanka, et al.
Publicado: (2020)

Anti-Tumor Necrosis Factor-α Therapy in the Management of Psoriasis and B-Chronic Lymphocytic Leukemia
por: Balato, Anna, et al.
Publicado: (2011)

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab
por: Ghoneim, Sara, et al.
Publicado: (2017)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
por: Kazemi, Tiana, et al.
Publicado: (2017)

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
por: Hawkes, Jason E., et al.
Publicado: (2021)

Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis
por: Huang, He, et al.
Publicado: (2023)

Ixekizumab for the Treatment of Acrodermatitis Continua of Hallopeau and Inverse Psoriasis
por: Xia, Rui Yuan, et al.
Publicado: (2023)

Polymorphic Light Eruption: What's New in Pathogenesis and Management
por: Lembo, Serena, et al.
Publicado: (2018)

Atopic Dermatitis: Epidemiology and Clinical Phenotypes
por: Raimondo, Annunziata, et al.
Publicado: (2021)

Immuno-Pathogenesis of Chronic Inflammatory Skin Diseases: Novel Molecular Targets and Biomarkers
por: Raimondo, Annunziata, et al.
Publicado: (2022)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
por: Hanley, Tessa L, et al.
Publicado: (2017)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)

Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient
por: Vinaixa Aranzazu, Arrieta, et al.
Publicado: (2021)

Ixekizumab for Patients with Plaque Psoriasis Affected by Multiple Sclerosis: Case report
por: Herrera-Acosta, Enrique, et al.
Publicado: (2021)

Stimulus whitening improves the efficiency of reverse correlation
por: Compton, Alexis, et al.
Publicado: (2022)

Cutaneous Eruption after SARS-CoV-2 Vaccine in Psoriatic Patient Treated with Methotrexate
por: Serena, Lembo, et al.
Publicado: (2022)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
por: Li, Ying, et al.
Publicado: (2022)

Case Report: Challenges in the Diagnosis of a Case of Mal de Meleda and a Therapeutic Attempt of Ixekizumab and Adalimumab
por: Dai, Yuwei, et al.
Publicado: (2022)

A Patient with Adalimumab-Induced Refractory Paradoxical Palmoplantar Pustulosis Was Successfully Treated by Ixekizumab: A Case Report
por: Shao, Xin-Yi, et al.
Publicado: (2023)

Ixekizumab in scalp psoriasis: Clinical, dermoscopical, and in vivo reflectance confocal microscopy evaluation
por: Ocampo‐Garza, Sonia Sofia, et al.
Publicado: (2022)

Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
por: PAPP, Kim, et al.
Publicado: (2022)

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
por: Burlando, Martina, et al.
Publicado: (2022)

Correction to: Stimulus whitening improves the efficiency of reverse correlation
por: Compton, Alexis, et al.
Publicado: (2022)

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Corrigendum: Case report: Challenges in the diagnosis of a case of Mal de Meleda and a therapeutic attempt of ixekizumab and Adalimumab
por: Dai, Yuwei, et al.
Publicado: (2022)

Psoriasis patients utilizing secukinumab, ixekizumab, or brodalumab – comparisons to prior biologic medication adherence levels, reasons for switching, and reported changes in disease symptoms
por: Baiano, Renee, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b7rr6dqk1d8enogmqah2o1is91